Sanofi draws fire over cost of MS drug Lemtrada Reuters via Yahoo! Maktoob News Wed, 31 Oct 2012 17:03 PM PDT PARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators. The journal, which published the encouraging results of two late-stage Lemtrada tests on Thursday, also criticized the drugmaker's decision to withdraw leukemia therapy Campath, the same drug given ... | Mumps outbreak traced to face-to-face schooling Reuters via Yahoo! News Wed, 31 Oct 2012 15:06 PM PDT NEW YORK (Reuters Health) - A face-to-face educational technique used among Orthodox Jews apparently led to an outbreak of mumps in 2009 and 2010 even though most of those infected were properly vaccinated, according to a new study. The outbreak, detailed in the November 1 New England Journal of Medicine, illustrates how close repeated contact with an infected person can overwhelm the mumps ... | Ivermectin hair lotion found effective against lice Reuters via Yahoo! Canada News Wed, 31 Oct 2012 15:05 PM PDT NEW YORK (Reuters Health) - A single 10-minute hair application of a drug used in oral form since the 1980s to control river blindness and other parasitic diseases eliminated head lice in nearly three of four children in a new study. The lotion contains ivermectin and is sold under the brand name Sklice by Sanofi Pasteur, which paid for the study. The U.S. Food and Drug Administration used the ... | | |
|
No comments:
Post a Comment